Physician profile
Paul Tseng
NPI 1811990484
$9,833.46
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,404 · 2020: $2,557 · 2021: $224 · 2022: $598 · 2023: $2,010 · 2024: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,422 · Food and Beverage: $1,619 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,422.31 |
| Food and Beverage | $1,618.98 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,174.47 | 2019-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $2,325.01 | 2020-2022 | |
| Foundation Medicine, INC. | $546.42 | 2019-2023 | |
| Abbvie INC. | $361.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $289.84 | 2019-2020 | |
| Tesaro, INC. | $280.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $222.92 | 2019-2023 | Lynparza |
| Eisai INC. | $145.59 | 2020-2024 | |
| Coopersurgical, INC. | $130.73 | 2019 | |
| Clovis Oncology, INC. | $112.82 | 2020 | |
| Myriad Genetic Laboratories, INC. | $102.46 | 2021 | |
| Ethicon US, LLC | $38.99 | 2019 | |
| Covidien LP | $38.59 | 2019 | |
| Bard Access Systems, INC. | $24.69 | 2019 | |
| Amgen INC. | $23.78 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.